Research

Dr Cohen has done the following research:

  • A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficacy, safety, tolerability and usability up to 5 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFα agents
  • A randomized, controlled study of sarilumab and methotrexate (MTX) versus etanercept and MTX in patients with rheumatoid arthritis (RA) and an inadequate response to 4 months of treatment with adalimumab and MTX
  • A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol
  • A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of AZD1722 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or
  • Ischemic Stroke in Patients with Type 2 Diabetes
  • Effect of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R on symptoms of irritable bowel syndrome: a double-blind, randomized, placebo-controlled study
  • Efficacy, pharmacokinetics, and safety of BI 695500 versus rituximab in patients with moderately to severely active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial.
  • A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients With or Without Statin Intolerance
  • A Phase 3B Study To Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with Stable Cardiovascular Disease and Glucose Abnormalities
  • Effects of 4-week Bifidobacterium lactis HN019 Supplementation on Whole Gut Transit Time and Gastrointestinal Symptoms in Adults with Constipation: A Double-blind, Randomized, Placebo controlled Dose-ranging Trial
  • A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Safety and Efficacy of GRT6005 in Patients with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
  • A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
  • A Multi-center Double-blind, Randomized, Controlled Trial to Evaluate the Effectiveness and Safety of Co-administered Traumeel® and Zeel® Intra-articular Injections versus Placebo Intra-articular Injections in Patients with Moderate-to-Severe Pain Associated with Osteoarthritis of the Knee
  • A Multi-center, Randomized, Double Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Monotheraphy Compared with Placebo in Patients with Type 2 Diabetes Mellitus (T2D) who are Drug-Naïve to Anti-Hyperglycemic Therapy
  • A Multi-center, Randomized, Double Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Plus Metformin Combination Therapy Compared with Placebo Plus Metformin in Patients with Type 2 Diabetes Mellitus (T2D) Inadequately Controlled with Metformin Monotherapy
  • A Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1033 in Subjects with Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
  • Multicenter, Double-blind, Placebo-controlled, Randomized, Three-treatment, Parallel Design Bioequivalence Study Comparing the Mylan’s Acyclovir Cream to GSK’s Zovirax® Cream in the Treatment of Recurrent Herpes Simplex Labialis
  • A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who are Intolerant to Statins
  • A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy
  • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
  • A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events
  • A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects with Gout and Cardiovascular Comorbidities
  • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed Dose Study to Evaluate the Efficacy, Safety, and Tolerability of Dexmecamylamine in the Treatment of Subjects with Overactive Bladder (OAB)
  • A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 30 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time
  • A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Z160 In Subjects With Postherpetic Neuralgia
  • A Phase 4 Trial Assessing the Impact of Residual Inflammation Detected via Imaging Techniques, Drug Levels and Patient Characteristics on the Outcome of Dose Tapering of Adalimumab in Clinical Remission Rheumatoid Arthritis (RA) Subjects
  • A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 with Rituximab in Subjects with Moderate to Severe Rheumatoid Arthritis
  • A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis
  • A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects with Moderate to Severe Rheumatoid Arthritis
  • A Randomized, Placebo-Controlled, Double-Blind, Study to Evaluate the Safety and Efficacy of Three Intra-Articular Injections of AMPION™ (4 ML) Administered Two Weeks Apart in Adults with Pain Due to Osteoarthritis of the Knee
  • A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms with Prior Loperamide Use
  • A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Apitox in Subjects with Osteoarthritis of the Knee
  • A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study with a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation- Predominant Irritable Bowel Syndrome
  • A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
  • A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
  • A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis
  • A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist
  • A Randomised, Double-blind, Chronic Dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab (MEDI-563) in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations
  • Clinical Knee Osteoarthritis Symptom Treatment 1 Study A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Knee Osteoarthritis Associated with Bone Marrow Lesions
  • A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia
  • An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia
  • A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients with Chronic Idiopathic Constipation
  • A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Pitavastatin CR 8 mg on the Reduction of LDL-C after 12 Weeks of Administration in Patients with Primary Hyperlipidemia or Mixed Dyslipidemia
  • A Multi-Center, Double-Blind, Randomized Vehicle-Controlled, Parallel- Group Study to Compare Perrigo UK FINCO’s Acyclovir Cream, 5% with ZOVIRAX® (Acyclovir) Cream 5%, and both Active Treatments to a Vehicle Control in Treatment of Recurrent Herpes Simplex Labialis
  • Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects with Signs and Symptoms of Osteoarthritis of the Hip or Knee
  • A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) versus Oseltamivir for the Treatment of
  • Influenza in Adults at Risk for Complications
  • A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events
  • A Phase 3, Randomized, Double-Blind, Active-controlled, Multicenter Study of the Long-term Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects with Osteoarthritis of the Hip or Knee
  • A Phase 3, Multicenter, Long-term Observational Study of Subjects From Tanezumab Studies who Undergo a Total Knee, Hip or Shoulder Replacement
  • Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment with Ertugliflozin (MK-8835/PF-04971729) in Subjects with Type 2 Diabetes Mellitus and Established Vascular Disease
  • A Phase 3 Randomized, Double-Blind Study Assessing the Efficacy and Safety of PF-06438179 and Infliximab in Combination with Methotrexate in Subjects with Moderately to Severely Active
  • Rheumatoid Arthritis who Have Had an Inadequate Response to Methotrexate
  • A Phase 3 Randomized, Double-Blind Study Assessing the Efficacy and Safety of PF-06410293 and Adalimumab in Combination with Methotrexate in Subjects with Moderately to Severely Active Rheumatoid Arthritis who Have Had an Inadequate Response to Methotrexate
  • A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN475 in Patients with Pain due to Osteoarthritis of the Knee or Hip
  • A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients with active rheumatoid arthritis, previously treated with Rituxan® or MabThera®
  • A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
  • An Open-Label, Long-Term Safety and Tolerability Study of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
  • A phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients with Postherpetic Neuralgia
  • A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus
  • A Phase 4 Trial Assessing the Impact of Residual Inflammation Detected via Imaging Techniques, Drug Levels and Patient Characteristics on the Outcome of Dose Tapering of Adalimumab in Clinical Remission Rheumatoid Arthritis (RA) Subjects (PREDICTRA)
  • A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms with Prior Loperamide Use (RELIEF)
  • A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults with Pain Due to Severe Osteoarthritis of the Knee
  • An Open Label Extension Study to Assess the Safety of Long-Term Treatment with a 4 ML Intra-Articular Injection of Ampion™ in Adults with Pain Due to Severe Osteoarthritis of the Knee
  • A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis
  • Clinical Knee Osteoarthritis Symptom Treatment 1 Study A Randomized, Double-blind, Placebo- controlled Trial to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate)
  • Administered Orally to Subjects with Knee Osteoarthritis Associated with Bone Marrow Lesions
  • A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS- 986165 in Subjects with Systemic Lupus Erythematosus
  • A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patient on a Background of Limited Standard of Care
  • A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated with Maximally Tolerated Statin Therapy
  • Comparative and Pragmatic Study of Simponi Aria versus Remicade in Rheumatoid Arthritis
  • A Multicenter, 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease
  • A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging, Phase 2b Study to Investigate the Efficacy of ESN364 in Postmenopausal Women Suffering From Vasomotor Symptoms
  • A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of SER 109 vs. Placebo to Reduce Recurrence of ClOstRidium difficile Infection (CDI) in Adults Who Have Received Antibacterial Drug Treatment for Recurrent CDI (RCDI)
  • An Open-Label Extension of Study SERES-012 Evaluating SER-109 in Adult Subjects with Recurrent Clostridium Difficile Infection (RCDI)
  • A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy of TG-C in Subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee